These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35421909)

  • 21. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort.
    Wang X; Cui Z; Zhang YM; Qu Z; Wang F; Meng LQ; Cheng XY; Liu G; Zhou FD; Zhao MH
    Nephrol Dial Transplant; 2018 Sep; 33(9):1558-1563. PubMed ID: 29149305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
    Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
    Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China.
    Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y
    Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A novel approach to rapid induction of remission in primary membranous nephropathy].
    Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN
    Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
    Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
    Front Immunol; 2021; 12():738788. PubMed ID: 34721403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of clinical features between idiopathic membranous nephropathy patients with and without serum antibody against phospholipase A2 receptor.
    Zhang Q; Liu X; Zhang Z; Wu M; Huang B; Zhang Y; Liu B; Qi Z; Shan W; Wang L; Hu Z; Sun Z
    Medicine (Baltimore); 2019 Nov; 98(45):e17658. PubMed ID: 31702617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
    Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B
    Front Immunol; 2023; 14():1156470. PubMed ID: 37187749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Glomerular Mannose-Binding Lectin Deposition on the Prognosis of Idiopathic Membranous Nephropathy.
    Zhang Y; Liu Y; Liang L; Liu L; Tang X; Tang L; Chen P; Chen J; Wang Z; Cao W; Chen Q; Zhao N; Xu D
    Kidney Blood Press Res; 2020; 45(5):713-726. PubMed ID: 32894840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.
    Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL
    BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrinogen-albumin ratio predicts treatment response in phospholipase A2 receptor-associated membranous nephropathy with nephrotic syndrome.
    Duan S; Chen S; Chen C; Lu F; Pan Y; Lu Y; Li Q; Liu S; Zhang B; Mao H; Xing C; Yuan Y
    Ren Fail; 2024 Dec; 46(1):2359024. PubMed ID: 38832491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.
    Kumar V; Ramachandran R; Kumar A; Nada R; Suri D; Gupta A; Kohli HS; Gupta KL; Jha V
    Nephrology (Carlton); 2015 Aug; 20(8):572-5. PubMed ID: 26194981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.
    Xiao C; Liu Y; Zhang X; Luo L; Li X; Wang T; Tian Z; Qin X; Liu J
    J Clin Lab Anal; 2020 Sep; 34(9):e23368. PubMed ID: 32449206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary N-acetyl-β-glucosaminidase and estimated Glomerular filtration rate may identify patients to be treated with immuno-suppression at diagnosis in idiopathic membranous nephropathy.
    Bazzi C; Usui T; Rizza V; Casellato D; Gallieni M; Nangaku M
    Nephrology (Carlton); 2018 Feb; 23(2):175-182. PubMed ID: 27764902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary membranous nephropathy in children and adolescents: a single-centre report from South Asia.
    Ramachandran R; Nayak S; Kumar V; Kumar A; Agrawal N; Bansal R; Tiewsoh K; Nada R; Rathi M; Kohli HS
    Pediatr Nephrol; 2021 May; 36(5):1217-1226. PubMed ID: 33108509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study.
    Yan P; Fang X; Ke B
    Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of serum mannose-binding lectin, anti-phospholipase A2 receptor antibody and renal outcomes in idiopathic membranous nephropathy and atypical membranous nephropathy: a single center retrospective cohort study.
    Zhao Y; Cai M; Jiang Z; Dong B; Yan Y; Wang Y; Zuo L
    Ren Fail; 2022 Dec; 44(1):428-433. PubMed ID: 35272568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels.
    Xue C; Wang J; Pan J; Liang C; Zhou C; Wu J; Song S; Cui L; Zhang L; Liu Y; Dai B
    BMC Nephrol; 2023 Sep; 24(1):280. PubMed ID: 37740193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
    Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
    Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.
    Hanset N; Esteve E; Plaisier E; Johanet C; Michel PA; Boffa JJ; Fievet P; Mesnard L; Morelle J; Ronco P; Dahan K
    Kidney Int Rep; 2020 Mar; 5(3):331-338. PubMed ID: 32154454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.